Neurogene (NGNE) Income from Continuing Operations (2013 - 2026)
Neurogene (NGNE) reported Income from Continuing Operations of 31097000.0 for Q1 2026, down 36.9% on a YoY basis from 49282659.25 in Q1 2025, and down 26.08% quarter-over-quarter from 24665000.0 in Q4 2025.
Neurogene (NGNE) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Neurogene has reported Income from Continuing Operations for 14 years, with the latest figure at 31097000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 36.9% year-over-year to 31097000.0; the trailing twelve-month figure through Mar 2026 stood at 100090000.0 (down 23.67% YoY), and the FY2025 full-year result was 91786000.0, down 23.78% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 31097000.0, down from 24665000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 11671000.0 in Q4 2022, with the low at 31097000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 18038764.71 across 5 years, with a median of 16462000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations rose 25.3% — and 2024, when it slumped 57.15%.
- Neurogene's Income from Continuing Operations stood at 11671000.0 in 2022, then slipped by 19.69% to 13969000.0 in 2023, then slumped by 37.76% to 19244000.0 in 2024, then dropped by 28.17% to 24665000.0 in 2025, then dropped by 26.08% to 31097000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 31097000.0 (Q1 2026), 24665000.0 (Q4 2025), and 21101000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | -31.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.10 Mn |
| Dec 31, 2025 | -24.67 Mn |
| Sep 30, 2025 | -21.10 Mn |
| Jun 30, 2025 | -23.23 Mn |
| Mar 31, 2025 | -22.72 Mn |
| Dec 31, 2024 | -19.24 Mn |
| Sep 30, 2024 | -20.34 Mn |
| Jun 30, 2024 | -18.63 Mn |
| Mar 31, 2024 | -16.46 Mn |
| Dec 31, 2023 | -13.97 Mn |
| Sep 30, 2023 | -14.57 Mn |
| Jun 30, 2023 | -11.86 Mn |
| Mar 31, 2023 | -12.26 Mn |
| Dec 31, 2022 | -11.67 Mn |
| Sep 30, 2022 | -13.61 Mn |
| Jun 30, 2022 | -15.87 Mn |
| Mar 31, 2022 | -15.37 Mn |
| Dec 31, 2021 | -15.17 Mn |
| Sep 30, 2021 | -15.45 Mn |
| Jun 30, 2021 | -15.12 Mn |